Statin use and breast cancer risk in a large population-based setting
Statin use and breast cancer risk in a large population-based setting
复制标题
DOI：
10.1158/1055-9965.epi-06-0737
复制
发表时间：
2007-03-01
影响因子：
3.8
通讯作者：
Daling, Janet R.
中科院分区：
文献类型：
--
作者：
Boudreau, Denise M.;Yu, Onchee;Daling, Janet R.
背景：机制研究表明，3-羟基-3-甲基戊二酰辅酶A抑制剂（他汀类药物）降低乳腺癌的风险。观察性研究提供了混合result.Methods：为了评估他汀类药物的使用和乳腺癌的风险之间的关系，我们进行了一项队列研究，年龄在45至89岁的妇女在一个综合的医疗保健服务系统。他汀类药物使用和协变量的信息来自自动数据库。我们通过监测、流行病学和最终结果登记确定了乳腺癌病例。我们使用考克斯比例风险模型来估计风险比（HR）和95%置信区间（95%CI）浸润性乳腺癌他汀类药物使用者与nonusers.Results相比：在92,788名妇女研究1990年至2004年，中位随访时间为6.4年，2,707例乳腺癌被确定。在研究期间，7.4%的女性使用他汀类药物至少1年，中位使用时间为3.1年。我们发现他汀类药物使用者与非使用者相比，乳腺癌风险无差异（HR，1.07; 95%CI，0.88-1.29）。乳腺癌的风险在使用持续时间（1-2.9，3-4.9，或>= 5年）或疏水性他汀类药物使用方面没有差异。我们发现使用他汀类药物≥ 5年的患者乳腺癌风险增加（任何他汀类药物的HR，1.27; 95%CI，0.89-1.81;疏水性他汀类药物的HR，1.47; 95%CI，0.89-2.44）和雌激素受体阴性肿瘤的风险（1-2.9年：HR，1.33; 95%CI，0.64-2.77; 3-4.9年：HR，1.68; 95%CI，0.72-3.92; >= 5年：HR，1.81; 95%CI，0.75-4.36）.结论：本研究不支持他汀类药物使用与乳腺癌风险之间的相关性。
Background: Mechanistic studies suggest that 3-hydroxy-3-methylglutaryl CoA inhibitors (statins) reduce the risk of breast cancer. Observational studies offer mixed results.Methods: To evaluate the relation between statin use and breast cancer risk, we conducted a cohort study among women ages 45 to 89 years within an integrated health care delivery system. Information on statin use and covariates were obtained from automated databases. We identified breast cancer cases through the Surveillance, Epidemiology, and End Results registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for invasive breast cancer among statin users compared with nonusers.Results: Among 92,788 women studied from 1990 to 2004, median follow-up time was 6.4 years, and 2,707 breast cancer cases were identified. During the study period, 7.4% of women used statins for at least 1 year, and the median duration of use was 3.1 years. We found no difference in breast cancer risk among statin users (HR, 1.07; 95% CI, 0.88-1.29) compared with nonusers. Risk of breast cancer did not differ by duration of use (1-2.9, 3-4.9, or >= 5 years) or hydrophobic statin use. We found a suggestive increased risk of breast cancer among statin users of >= 5 years (HR, 1.27; 95% CI, 0.89-1.81 for any statins and HR, 1.47; 95% CI, 0.89-2.44 for hydrophobic statins) and of estrogen receptor- negative tumors with increasing duration of statin use (1-2.9 years: HR, 1.33; 95% CI, 0.64-2.77; 3-4.9 years: HR, 1.68; 95% CI, 0.72-3.92; >= 5 years: HR, 1.81; 95% CI, 0.75-4.36).Conclusion: This study does not support an association between statin use and breast cancer risk.